Health, Beauty And Wellness News: Wellements, Le-Vel, Nutrition 21, Delictase
This article was originally published in The Rose Sheet
Executive Summary
Wellements adds infant product; Le-Vel Thrive for Rise Against Hunger; sales post promotions at Nutrition 21; and Delictase reaches colic symptoms.
You may also be interested in...
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Mandatory Product Listing: Needed For US VMS Market, Not Mandatory In User Fee Bill – CRN
Establishing VMS products MPL as stated within legislation to re-authorize FDA user fee programs for drugs, biologics and medical device applications isn’t urgent enough to prevent passing user fee bill, says CRN chief Steve Mister.
Hepatitis C Treatment Restrictions In Spotlight After HHS Report
Study finds one-third of insured adults have access to hepatitis C treatment within 360 days of the first positive test. CDC suggests treating all eligible patients without restrictions and eliminating preauthorization requirements. For state Medicaid programs, 38 states require prior authorization and 12 states have substance use restrictions.